Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ROIV - Review Myovant Sciences And A Consideration Of Steps Following Commercial Launch

ROIV - Review Myovant Sciences And A Consideration Of Steps Following Commercial Launch

Roivant Sciences Ltd.
  • Relugolix is approved and launched in two indications and could establish itself as a new Standard of Care.
  • The inked 4.2 billion deal with top-class partner Pfizer verifies the blockbuster potential of Relugolix.
  • Quarterly reports reflect initial sales success and combined with strong fundamentals, this should drive the company's valuation.
  • In the long term, Myovant aims to become a relevant player in the field of women's health or oncology.

For further details see:

Review Myovant Sciences And A Consideration Of Steps Following Commercial Launch
Stock Information
Company Name: Roivant Sciences Ltd.
Stock Symbol: ROIV
Market: NASDAQ
Website: roivant.com
Menu
ROIV ROIV Quote ROIV Short ROIV News ROIV Articles ROIV Message Board
Get ROIV Alerts

News, Short Squeeze, Breakout and More Instantly...